BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31096215)

  • 21. Cutting Edge: The Tetraspanin CD53 Promotes CXCR4 Signaling and Bone Marrow Homing in B Cells.
    Chakraborty M; Greenberg ZJ; Dong Q; Roundy N; Bednarski JJ; Paracatu LC; Duncavage E; Li W; Schuettpelz LG
    J Immunol; 2024 Apr; 212(7):1075-1080. PubMed ID: 38363205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
    Shin HC; Seo J; Kang BW; Moon JH; Chae YS; Lee SJ; Lee YJ; Han S; Seo SK; Kim JG; Sohn SK; Park TI
    Korean J Intern Med; 2014 Nov; 29(6):785-92. PubMed ID: 25378977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CXCL12-CXCR4 contributes to the implication of bone marrow in cancer metastasis.
    Shi J; Wei Y; Xia J; Wang S; Wu J; Chen F; Huang G; Chen J
    Future Oncol; 2014 Apr; 10(5):749-59. PubMed ID: 24799056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study.
    Lemma SA; Pasanen AK; Haapasaari KM; Sippola A; Sormunen R; Soini Y; Jantunen E; Koivunen P; Salokorpi N; Bloigu R; Turpeenniemi-Hujanen T; Kuittinen O
    Eur J Haematol; 2016 May; 96(5):492-501. PubMed ID: 26153511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemokine receptor - Directed imaging and therapy.
    Buck AK; Stolzenburg A; Hänscheid H; Schirbel A; Lückerath K; Schottelius M; Wester HJ; Lapa C
    Methods; 2017 Nov; 130():63-71. PubMed ID: 28916148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased expression of CXCR4 chemokine receptor in bone marrow after chemotherapy in patients with non-Hodgkin lymphomas is a good prognostic factor.
    Mazur G; Butrym A; Kryczek I; Dlubek D; Jaskula E; Lange A; Kuliczkowski K; Jelen M
    PLoS One; 2014; 9(5):e98194. PubMed ID: 24859274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Correlations of chemokine CXCL12 and its receptor to tumor metastasis].
    Jiang YP; Wu XH
    Ai Zheng; 2007 Feb; 26(2):220-4. PubMed ID: 17298758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemokine (C-X-C motif) ligand 12 is associated with gallbladder carcinoma progression and is a novel independent poor prognostic factor.
    Lee HJ; Lee K; Lee DG; Bae KH; Kim JS; Liang ZL; Huang SM; Suk Oh Y; Kim HY; Jo DY; Min JK; Kim JM; Lee HJ
    Clin Cancer Res; 2012 Jun; 18(12):3270-80. PubMed ID: 22553346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia.
    van den Berk LC; van der Veer A; Willemse ME; Theeuwes MJ; Luijendijk MW; Tong WH; van der Sluis IM; Pieters R; den Boer ML
    Br J Haematol; 2014 Jul; 166(2):240-9. PubMed ID: 24697337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downregulation of CXCR4 by SDF-KDEL in SBC-5 cells inhibits their migration in vitro and organ metastasis in vivo.
    Ma N; Pang H; Shen W; Zhang F; Cui Z; Wang J; Wang J; Liu L; Zhang H
    Int J Mol Med; 2015 Feb; 35(2):425-32. PubMed ID: 25504108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival.
    Mirisola V; Zuccarino A; Bachmeier BE; Sormani MP; Falter J; Nerlich A; Pfeffer U
    Eur J Cancer; 2009 Sep; 45(14):2579-87. PubMed ID: 19646861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone Marrow Molecular Markers Associated with Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma.
    Wang D; Liu P; Zhang Y; Liu HY; Shen D; Che YQ
    Biomed Res Int; 2018; 2018():1042597. PubMed ID: 30534553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expressions of VEGF and CXCR4 in diffuse large B cell lymphoma and their clinical significances].
    Guo Q; Wang JJ; Li F; Yang HL; Yu Y; Zhao ZG; Wang XF; Wang YF; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):383-6. PubMed ID: 23628037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The good and bad faces of the CXCR4 chemokine receptor.
    Teixidó J; Martínez-Moreno M; Díaz-Martínez M; Sevilla-Movilla S
    Int J Biochem Cell Biol; 2018 Feb; 95():121-131. PubMed ID: 29288743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The CXCR4/CXCL12 axis in cutaneous malignancies with an emphasis on melanoma.
    Mitchell B; Mahalingam M
    Histol Histopathol; 2014 Dec; 29(12):1539-46. PubMed ID: 24879309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy.
    Teagle AR; Barton H; Charles-Edwards E; Dizdarevic S; Chevassut T
    Acta Radiol; 2017 Dec; 58(12):1476-1484. PubMed ID: 28382828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human Cytomegalovirus UL111A and US27 Gene Products Enhance the CXCL12/CXCR4 Signaling Axis via Distinct Mechanisms.
    Tu CC; Arnolds KL; O'Connor CM; Spencer JV
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.
    Yao Z; Deng L; Xu-Monette ZY; Manyam GC; Jain P; Tzankov A; Visco C; Bhagat G; Wang J; Dybkaer K; Tam W; Hsi ED; van Krieken JH; Ponzoni M; Ferreri AJM; Møller MB; Winter JN; Piris MA; Fayad L; Liu Y; Song Y; Orlowski RZ; Kantarjian H; Medeiros LJ; Li Y; Cortes J; Young KH
    Leukemia; 2018 Feb; 32(2):353-363. PubMed ID: 28745330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CXCR4 can induce PI3Kδ inhibitor resistance in ABC DLBCL.
    Kim JH; Kim WS; Ryu KJ; Kim SJ; Park C
    Blood Cancer J; 2018 Feb; 8(2):23. PubMed ID: 29472546
    [No Abstract]   [Full Text] [Related]  

  • 40. Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma.
    Lapa C; Hänscheid H; Kircher M; Schirbel A; Wunderlich G; Werner RA; Samnick S; Kotzerke J; Einsele H; Buck AK; Wester HJ; Grigoleit GU
    J Nucl Med; 2019 Jan; 60(1):60-64. PubMed ID: 29777009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.